EEF2K (eukaryotic elongation factor 2 kinase) is a calcium/calmodulin-dependent threonine kinase that serves as a critical regulator of protein synthesis by controlling translational elongation 1. Upon activation by upstream kinases including AMPK, EEF2K phosphorylates eukaryotic elongation factor 2 (eEF2) at threonine 56, rendering it inactive and unable to bind ribosomes, thereby reducing the rate of protein synthesis 2. This regulatory mechanism operates under cellular stress conditions such as nutrient deprivation, hypoxia, and oxidative stress to conserve cellular energy and support cell survival 3. EEF2K demonstrates significant disease relevance, being highly expressed in triple-negative breast cancer (TNBC) and associated with poor prognosis 4. The kinase also plays protective roles in cardiovascular diseases, alleviating doxorubicin-induced cardiotoxicity by inhibiting GSK3β and improving autophagy dysfunction 5. Clinically, EEF2K represents a promising therapeutic target, with novel degrader compounds showing potent anti-cancer activity against TNBC in preclinical studies 6. Additionally, EEF2K regulation is modulated by exercise training in skeletal muscle, affecting muscle protein synthesis through various signaling pathways 7.